Valneva SE - ADR

NASDAQ:VALN

27.85

+0.59 (+2.16%)

Market Cap (Intraday)	1.39B
Current PE	N/A
Forward PE	N/A
2yr Forward PE	6.81

See more stats

Estimates Current Quarter

Revenue	$28.43 Million
Adjusted EPS	-$0.90

See more estimates

10-Day MA	N/A
50-Day MA	N/A
200-Day MA	N/A

See more pivots

Valneva SE - ADR Stock, NASDAQ:VALN

Campus Bio-Ouest, 6, rue Alain Bombard, Saint-Herblain, Grand Est 44800

Phone: +33.2.28.07.37.10

Number of Employees:

http://www.valneva.com

Description

Valneva SE is a biotech company. The firm engages in the development, production and marketing of vaccine and preventive medicine. It operates through the following segments: Commercialized Vaccines, Technologies and Services and Vaccine Candidates. The Commercialized Vaccines segment includes currently marketed vaccines of the group such as JEV and DUKORAL. The Technologies and Services segment regroups services and inventions in commercialization stage. The Vaccine Candidates segment consists of proprietary research and development programs aiming to generate new approvable products. The company was founded on April 7, 1999 and is headquartered in Saint-Herblain, France.